IRCT20170122032121N8招募中1 期
Safety and efficacy evaluation post intravenous infusion of activated NK cells in recurrent and refractory of high-risk neuroblastoma patients: a phase I/IIa clinical trial
Kian immune cell company0 个研究点目标入组 10 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 years 至 16 years（—）
- 性别
- All
入选标准
- •High-risk neuroblastoma that is resistant to standard induction therapy based on COG (Children’s Oncology Group) criteria (according to INRG criteria and having received at least 4 cycles of multi-drug induction chemotherapy, and not responding to conventional treatments).
- •Evidence of relapse or progression of neuroblastoma after autologous peripheral blood stem cell transplantation or aggressive therapy.
- •A minimum life expectancy of 6 months.
- •Patients must have a pathological diagnosis of neuroblastoma and/or confirmation of tumor cells in the bone marrow with increased urinary catecholamines.
- •Measurable residual disease based on imaging findings using Curie scoring or MIBG or PET imaging criteria (1: measurable tumor of at least 10 mm in one dimension on MRI or CT scan with positive uptake on I-123 MIBG scan (MIBG avid”) or 2) increased FDG uptake on 18F-FDG PET-CT or PET-MRI (PET avid”)).
排除标准
- •Insufficient bone marrow function: Platelet count > 50,000/µL, independent of transfusion (no platelet transfusion within one week).Absolute neutrophil count (ANC) maximum of 500 per microliter.Hemoglobin > 10 grams per deciliter.
- •Insufficient liver function: Plasma bilirubin level more than 1.5 times the upper limit of normal (ULN).SGPT (ALT) at least three times the upper limit of normal (a level of 45 units per liter is considered the upper limit of normal).
- •Insufficient kidney function: Creatinine clearance or estimated radioisotope GFR < 70 ml/min/1.73m².Plasma creatinine level more than 1.5 times the upper limit of normal based on age/gender.
- •Insufficient central nervous system functionIf seizures are present, entry into the study is not possible if seizures are not well controlled with anticonvulsant drugs.CNS toxicity > Grade 2.
- •Insufficient cardiovascular functionShortening fraction < 27% by ECHO OREjection fraction < 50% by ECHO or gated radionuclide study.
- •Insufficient pulmonary functionEvidence of dyspnea at rest.Exercise intolerance.Chronic need for oxygen and room air pulse oximetry < 94% if pulse oximetry evaluation is clinically indicated.Presence of current pleural or pericardial effusion.
- •Inability to tolerate new treatment due to emergency conditions.
- •Elevated catecholamines (more than twice the ULN) or sole involvement of bone marrow (bone marrow positive for NB as the only evaluable disease without confirmatory pathology report).
- •Receiving 0.5 mg/kg/day of systemic steroids (equivalent to prednisone) for at least 7 days before enrollment.
- •Receiving CYP3A4 inducers or inhibitors at least 7 days before study enrollment.
- •Diagnosis of any other malignancy alongside the diagnosis of neuroblastoma.
- •Diarrhea > Grade 2 (4 to 6 stools per day).
- •Significant illness not covered by exclusion criteria but interfering with the study process or increasing the intensity of treatment with NK cells.
- •Participation in another clinical trial.
- •Severe impairment of major organ functions, such as renal, cardiac, hepatic, neurological, pulmonary, or gastrointestinal toxicity above Grade 2 according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 5.0 (CTC v5.0).
- •Inability to comply with protocol requirements.
- •Lack of confirmed and signed consent by the patient's guardians.
- •Evidence of HIV disease (Human Immunodeficiency Virus) or positive serology for HIV.
研究者
相似试验
已完成
2 期
Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patientsIRCT20151227025726N20Shahid Beheshti University of Medical Sciences80
进行中（未招募）
1 期
Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency AnemiaEUCTR2019-003821-70-PLAmerican Regent, Inc.10
招募中
2 期
Investigating the effect of the bone marrow-drived mesenchymal stem cells in MS patients under fingolimod therapy.Multiple sclerosisIRCT20191004044975N1Vice-presidency for science and technology120
已完成
不适用
Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancerBreast cancerJPRN-UMIN000006710Shiga University of Medical Science30
尚未招募
4 期
Comparing Tramadol vs Paracetamol for Pain Relief in Acute Pancreatitis: A Randomized Controlled TrialCTRI/2024/06/068751DR ABHIJEET SHRIDHAR